Recombinant factor VIIa treatment for life-threatening haemoptysis

Respirology. 2006 Sep;11(5):652-4. doi: 10.1111/j.1440-1843.2006.00906.x.

Abstract

Diffuse alveolar haemorrhage is a severe clinical disorder that may be life-threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, recombinant factor VIIa has been used successfully for the treatment of bleeding in patients without pre-existing coagulopathy. We describe the successful use of recombinant factor VIIa in a patient with diffuse alveolar haemorrhage secondary to pulmonary-renal syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Coagulants / therapeutic use*
  • Factor VIIa / therapeutic use*
  • Hemoptysis / drug therapy*
  • Hemoptysis / pathology
  • Humans
  • Male
  • Pulmonary Alveoli*
  • Recombinant Proteins / therapeutic use

Substances

  • Coagulants
  • Recombinant Proteins
  • Factor VIIa